About 12 results found for searched term "56-73-5" (0.119 seconds)
| Cat.No. | Name | Target |
|---|---|---|
| M14193 | Cav 2.2 blocker 1 | Calcium Channel |
| Cav 2.2 blocker 1 (compound 9) is a N-type calcium channel (Cav 2.2) blocker for the treatment of pain, with an IC50 of 1 nM. | ||
| M17341 | Alnusdiol | Phenols |
| Alnusdiol | ||
| M25522 | UMB298 | Epigenetic Reader Domain |
| UMB298 is a potent and selective CBP/P300 bromodomain inhibitor. | ||
| M3747 | CID755673 | PKD |
| CID755673 is a potent and selective cell-active small molecule inhibitor for PKD with an IC50 of 182 nM. | ||
| M6164 | MCC950 | Pyroptosis |
| CP-456773 | ||
| MCC950 (CP-456773) is a potent, selective NLRP3 inhibitor with IC50 of 7.5 nM and 8.1 nM in BMDMs and HMDMs, respectively. | ||
| M8083 | MCC950 sodium salt (CP-456773) | Pyroptosis |
| CP-456773 sodium; CRID3 sodium salt | ||
| MCC950 (CP-456773) sodium salt is a potent, selective NLRP3 inhibitor with IC50s of 7.5 and 8.1 nM in BMDMs and HMDMs, respectively. MCC950 specifically inhibits NLRP3 but not AIM2, NLRC4 or NLRP1 activation. | ||
| M8382 | kb-NB142-70 | Others |
| kb-NB142-70 is a derivative of the PKD1 inhibitor CID755673, with approximately 6-fold greater potency (IC50 for inhibition of PKD1 = 28. | ||
| M24827 | Talacotuzumab | IL Receptor/Related |
| JNJ 56022473; CSL 362 | ||
| Talacotuzumab (JNJ 56022473; CSL 362) is an IgG1-type fully humanized, CD123-neutralizing monoclonal antibody containing a modified Fc structure. Talacotuzumab has KDs of 0.43 nM, 188 nM, 46 nM, 16.8 nM for CD123, CD32b/c, CD16-158F, CD16-158V, respectively. Talacotuzumab inhibits IL-3 binding to CD123, antagonizing IL-3 signaling in target cells. Talacotuzumab has mutated the Fc region to increase affinity for CD16 (FcγRIIIa), thereby enhancing antibody-dependent cell-mediated cytotoxicity (ADCC). Talacotuzumab is highly effective in vivo reducing leukemic cell growth in acute myeloid leukemia (AML) xenograft mouse models. | ||
| M29579 | CCT373566 | Bcl-2 |
| CCT373566 is a potent and orally active degrader of transcriptional repressor BCL6, with an IC50 of 2.2 nM. CCT373566 shows strong antiproliferative efficacy in vitro and reduction in tumor growth in vivo. | ||
| M29964 | SB-423557 | Calcium-sensing Receptor |
| SB-423557 is an orally active calcium-sensing receptor (CaR) antagonist (IC50=520 nM), precursor of SB-423562 (IC50=73 nM). SB-423557 is well tolerated in human and increases plasma concentrations of exogenous parathyroid hormone (PTH) and stimulates bone formation. | ||
| M45123 | GSK256073 | GPR/FFAR |
| GSK256073 is a potent, selective, orally active GPR109A agonist and a potent and persistent HCA2 agonist with a pEC50 of 7.5 (Human HCA2). In addition, GSK256073 significantly improves glucose homeostasis by inhibiting lipid degradation and has potential for the study of type 2 diabetes mellitus (T2DM) and dyslipidemia. | ||
| M45148 | Vari Fluor 568 SE | Fluorescent Dye |
| VF 568 SE | ||
| Vari Fluor 568 SE is a Vari Fluor SE series labeling dye (Ex/Em=573 nm/595 nm).The Vari Fluor SE series of dyes is a class of fluorescent dyes containing NHS ester groups for labeling antibodies, proteins, peptides, amine-modified oligonucleotides, and free amines (-NHX) on other biomolecules. | ||
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2024 AbMole BioScience. All Rights Reserved.
